The Pre-Hire Diagnostic Every Medtech Founder Should Run on a Healthcare Public Relations Agency

Founders walking into their first healthcare public relations agency meeting share the same expectation. The healthcare public relations agency conversation is one of the most consistently misframed decisions in medtech commercial strategy.

Founders hire an agency expecting press releases, media hits, and a fuller Google News page. The medtech PR narrative that really closes deals with strategics comes from a completely different kind of engagement.

Great companies don't wait for markets to form. They engineer them, and the healthcare public relations agency that supports that engineering is a category-and-narrative shop, not a press release factory.

Over 400+ episodes of State of MedTech, the pattern is consistent.

Teams that treat healthcare PR as media relations get media mentions. Companies that treat it as market engineering get the category authority signal and the strategic conversations that produce acquisitions.

Key Takeaways

• The healthcare public relations agency medtech founders think they're hiring produces press releases. The one they need produces category creation, market narrative, and the founder voice that closes deals with strategics.
• TMINI created the miniature robot category through non-traditional PR. That is the medtech PR narrative pattern that separates real category work from press release production.
• Boilerplate press releases signal PR team output, not founder voice. The healthcare public relations agency that produces real market position writes copy the founder could really say out loud.
• FDA clearance produces a brief inbound spike that fades. Announcements dressed up as market validation are traps. Real market validation is repeatable, measurable demand engineered before the announcement.
• Public category authority plus private strategic conversations is the two-track PR structure that produces acquisitions. Great companies don't wait for markets to form, and they don't wait for acquirers to notice them either.

Why the TMINI Category Creation Playbook Works

This came up in an episode about the $100B shift reshaping medtech markets:

"They're the ones who created this category of a miniature robot. And what I love is the fact that Stuart and his team have done this phenomenal job of taking a non-traditional playbook of PR. Recently, they just announced this press release about the TMINI doing its first case with the Stryker knee. But they have no partnership, no agreement, nothing."

That is the healthcare public relations agency operating model medtech founders should be paying for.

TMINI created the miniature robot category through consistent, non-traditional PR that positioned the company as the voice of a new segment. The announcement about the first case with a Stryker knee reinforced the category framing even without a formal partnership.

Every media touchpoint extended the category narrative TMINI was engineering, and the market started attaching the miniature robot category to TMINI's name.

That is the medtech PR narrative pattern.

Category creation through consistent narrative work, reinforced by every media touchpoint, compounded across eighteen months into a market position competitors have to respond to. Traditional PR agencies produce announcement volume. Non-traditional PR agencies produce category ownership.

The teams that compound category authority through PR hire on the category-creation spec. Medtech leaders who hire on the announcement-volume spec produce press releases that disappear within seventy-two hours of publication.

Why Boilerplate PR Copy Fails the Authenticity Test

That test came up in an episode about Amazon's $3.9B acquisition of One Medical:

"I highly recommend you don't have your pr team or somebody write that there's no way that somebody just said that off the top of their head there's just too many words."

That is the authenticity test every healthcare public relations agency deliverable should pass.

Boilerplate PR quotes signal PR team output. The market reads the boilerplate immediately, and the credibility of the founder's voice drops the moment the audience recognizes the polished corporate cadence.

The healthcare public relations agency that produces real market position writes copy the founder could really say out loud in a conversation. Every quote reads like the founder speaking, not like a communications professional performing.

That is what separates founder-led PR from corporate PR. Founder-led PR compounds authenticity across every media touchpoint. Corporate PR produces impressions the market registers as noise.

The companies that get medtech PR narrative right insist on this authenticity discipline from the first press release. Every quote gets read aloud before it ships.

If the founder would not say those exact words in a conversation with a physician friend, the copy gets rewritten. That discipline produces the durable founder voice that becomes the category voice over eighteen months.

Why FDA Announcements Never Really Validate Markets on Their Own

I made this exact point in an episode about how market engineering helps medtech startups raise capital:

"When you announce like getting through the FDA, they get a little bit inbound, they get some attention, everything, and that can last for like a week or two, and then the after effects of that can last for a couple of months and think that you have validated the market and reality you didn't."

That is the trap most medtech founders fall into with their healthcare public relations agency.

FDA clearance produces a brief inbound spike, with physicians reaching out and health systems asking about pilots. The founder concludes that the market has validated the product, budgets marketing accordingly, and then watches the inbound signal fade over the next quarter as the initial announcement cycle completes.

Real market validation is different.

It is repeatable, measurable demand that persists beyond the announcement cycle and grows month over month. That is what closes the traction gap between clearance and commercial adoption, and it is what separates market-product fit from a temporary announcement spike.

Clinical validation ≠ commercial traction, and FDA clearance is the starting line, not the finish line. The medtech PR narrative that closes deals shows evidence of the demand pattern that persists after the announcement fades, not just the announcement itself.

The healthcare public relations agency that produces real value builds the narrative infrastructure that produces persistent demand. Announcements become downstream reinforcement of a market position the founder has already engineered.

Traditional PR agencies produce the announcement without the market engineering underneath, and the founder ends up with an inbound spike that evaporates.

Why Public Category Authority Plus Private Strategic Conversations Compounds

That thread runs through an episode about 7 lessons from $17B in medtech exits every founder should study:

"You want to be able to be very public on social media doing thought founder led thought leadership the company's publishing trash and everything but then separately you want to have very private conversations with multiple strategics whose acquisition over you makes sense."

That is the two-track structure the healthcare public relations agency should be supporting for medtech founders.

The public track is founder-led category authority across LinkedIn, podcast appearances, trade press bylines, and category content. Every asset compounds the founder's voice as the category authority.

The private track is direct, ongoing strategic relationship-building with the specific strategics whose acquisition would produce the founder's exit outcome. Every conversation warms the strategic to the market position the public track is engineering.

Both tracks reinforce each other.

The public category authority makes the private conversations easier because the strategic already knows the founder as a category voice. The private conversations sharpen the public category authority because the founder learns exactly what the strategic prioritizes and can reflect that in the public content.

Traditional healthcare PR agencies produce the public track and stop. The medtech leaders who compound category authority for exit run both tracks in parallel.

And the healthcare public relations agency that supports that two-track structure is the one that produces the acquisition outcomes founders are really investing in when they hire PR.

Why Grand Announcements That Go Nowhere Are Category-Killers

That exact failure mode came up in an episode from Medtech Women 2023:

"They make for like really great press releases and like going up on panels to talk about this sort of like big thing in the future but then they end up either getting dissolved or like it goes nowhere."

That is the failure pattern the healthcare public relations agency has to protect founders against.

Grand announcements about future products, future partnerships, and future strategic direction produce short-term press hits and long-term credibility damage when the announced initiatives fail to materialize.

The market remembers the promise. When the promise doesn't land within twelve to eighteen months, the founder's credibility as a category voice drops materially.

Real medtech PR narrative work is the opposite.

Announcements are anchored to shipped outcomes. Every press release describes something that has already happened or is contractually committed. Every panel appearance references specific work already in motion, not future intentions.

That discipline is uncomfortable for companies that want to control the narrative with big announcements. It is what separates the healthcare public relations agencies that produce durable category authority from the agencies that produce announcement spikes followed by credibility slumps.

The operators who hire on the outcome-anchored spec compound. The operators who hire on the future-vision spec pay for their announcements twice.

Why the Two-Track PR Structure Compounds Faster With a Shared Editorial Calendar

The public track and the private track have to share an editorial calendar to compound efficiently.

Public category authority on LinkedIn should reference themes the founder will bring into strategic conversations that quarter. Private strategic conversations should reference themes the founder has published publicly.

Every strategic on the private list will search the founder's public content before every meeting.

If the two tracks are disconnected, the strategic reads the disconnection as inconsistency. If they are coordinated around a shared editorial calendar, the strategic reads consistency and category authority.

The healthcare public relations agency that runs this coordination as an operating discipline produces the fastest compounding across both tracks. Every public asset warms the private conversations.

Every private conversation sharpens the next public asset. And the founder's category voice compounds across every touchpoint the strategic experiences.

That coordination is what separates real medtech PR narrative work from traditional agency output.

Traditional agencies run the public track and never touch the private strategic relationship layer. Category-and-narrative shops run both in coordination and treat the editorial calendar as shared infrastructure between the two.

What This Means for Medtech Founders

The healthcare public relations agency medtech founders should hire is a category-and-narrative shop that supports founder-led category authority, private strategic relationship-building, and outcome-anchored announcements.

It has to deliver category creation instead of announcement volume.

It has to write copy the founder could really say out loud. It has to build market engineering infrastructure that produces persistent demand beyond any single announcement cycle, and it has to protect the founder from the grand-announcement trap that destroys credibility.

This is the same discipline behind why hiring a healthcare marketing agency before defining your category burns 12 months of medtech runway. PR and public relations are the same underlying market engineering exercise, seen through slightly different service labels.

So the healthcare public relations question isn't which agency can get you into the trade press. It's whether the agency can pass the three diagnostic questions. If they can, the engagement compounds into category authority and strategic acquirer familiarity. If they can't, the engagement produces announcements that never convert.

That's what we built MarketCraft to solve.

It's a market engineering practice that runs the two-track PR discipline alongside the founder across the eighteen-month window. Companies that hire on that spec close deals with strategics. The operators who hire on the press release spec produce announcement volume and no durable market position.

Agency Selection Discipline Separates the Two Outcomes

The medtech founders who compound category authority through healthcare public relations agency work all made the same choice from the first engagement.

They interviewed only category-and-narrative shops, asked to see the specific category creation work each had produced, and rejected any portfolio that showed announcement volume without evidence of durable category ownership.

That agency selection discipline is what separates founders who compound market position from founders who pay for announcements that disappear inside seventy-two hours. Getting it right is the difference between an eighteen-month program that produces a strategic acquisition conversation and one that produces nothing but a longer Google News page.

That gap in outcome is worth every hour founders invest in the initial agency vetting, and every quarter of budget discipline required to hold the eighteen-month operating window without pulling out mid-way.

Frequently Asked Questions

What Should Medtech Founders Look For in a Healthcare Public Relations Agency?

Category creation capability, founder-voice authenticity discipline, outcome-anchored announcement policy, and the ability to support both public category authority and private strategic relationship-building.

Traditional PR agencies deliver announcement volume. Real category-and-narrative shops deliver market position that compounds across the eighteen-month operating window.

How Should Medtech Founders Structure the Two-Track PR Approach?

Public track: founder-led category authority across LinkedIn, podcast, trade press, and category content. Private track: direct, ongoing strategic relationship-building with the specific strategics whose acquisition would produce the founder's exit outcome. Both tracks running in parallel is what produces acquisitions. Either alone stalls.

Why Are Boilerplate PR Quotes a Credibility Problem for Medtech Founders?

Boilerplate quotes signal PR team output. Audiences recognize the polished corporate cadence immediately, and the founder's authenticity drops the moment the market registers the pattern.

The healthcare public relations agency that produces real market position writes copy the founder could really say out loud in a conversation with a physician friend.

How Should Medtech Founders Time PR Announcements?

Anchor every announcement to shipped outcomes or contractually committed activity. Avoid grand future-vision announcements that produce short-term press and long-term credibility damage when the announced initiatives fail to materialize. Real medtech PR narrative work compounds credibility across every announcement. Speculative PR work erodes it.

What Does Category Ownership Look Like at Month Eighteen?

The market attaches the category name to the founder's company unprompted. Physicians reference the category using the founder's framing. Trade press attributes category thinking to the founder. Competitors respond to the founder's narrative in their own content.

That is the ownership signal the healthcare public relations agency is really engineering across the eighteen-month window, and it is the leading indicator of the acquisition conversations that produce medtech exits.

Listen to the Full Conversations

• This Month in Medtech: The $100B Shift Reshaping Markets
• Amazon's $3.9B Acquisition of One Medical and Why Jeff Bezos Doesn't Ghostwrite
• How Market Engineering Helps Medtech Startups Raise Capital
• 7 Lessons From $17B in Medtech Exits That Every Founder Should Study
• Medtech Women 2023 Panel

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, a leading podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.